Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (Nasdaq: KURA) is a biopharmaceutical company focused on precision medicines for cancer, and its news flow reflects the evolution of this strategy. Company announcements highlight progress with KOMZIFTI (ziftomenib), an oral menin inhibitor approved in the United States for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
News items for KURA commonly cover regulatory milestones, clinical data and commercial updates. Recent releases describe full FDA approval of KOMZIFTI, its addition to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology as a Category 2A recommended option for relapsed or refractory NPM1-mutated AML, and the start of U.S. commercial sales. Kura also reports on its collaboration with Kyowa Kirin, including milestone payments tied to clinical and commercial events.
Investors following KURA news can expect detailed coverage of clinical trial readouts from programs such as KOMET-001, KOMET-007 and KOMET-017, which evaluate ziftomenib across newly diagnosed and relapsed or refractory AML, often in combination with regimens like cytarabine/daunorubicin and venetoclax/azacitidine. Additional news addresses the company’s farnesyl transferase inhibitor programs, darlifarnib and tipifarnib, and their activity in solid tumors.
Kura’s press releases also include corporate updates such as financial results, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in scientific and investor conferences. For readers tracking KURA, this news page offers a centralized view of key developments in its precision oncology pipeline, regulatory interactions, collaborations and commercialization activities.
Kura Oncology (Nasdaq: KURA) announced that on March 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 44,700 shares under the company’s 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.68 (closing price on March 2, 2026) and vests over four years: 25% after one year and the remainder monthly over 36 months, subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) reported Q4 and full-year 2025 results and a corporate update on March 5, 2026. Key highlights: KOMZIFTI FDA-approved for R/R NPM1-mutant AML, generated $2.1M in Q4 product revenue, and achieved Orange Book patent protection through July 2044. Company ended 2025 with $667.2M in cash and expects $180M in collaboration payments to fund KOMET-017 through topline Phase 3 results anticipated in 2028.
Pipeline advances include pivotal KOMET-017 frontline trials, FIT-001 Phase 1b expansion, and multiple 2026 clinical data milestones across AML and solid tumors.
Kura Oncology (Nasdaq: KURA) will report its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss results and a corporate update.
Investors can access the live webcast and archived replay via the Investors section of the company website at www.kuraoncology.com.
Kura Oncology (Nasdaq: KURA) will participate in three investor conferences in March 2026: TD Cowen Health Care Conference on March 4 at 11:50 a.m. ET, Leerink Partners Global Biopharma Conference on March 10 at 10:40 a.m. ET, and Barclays Global Healthcare Conference on March 12 at 9:00 a.m. ET.
Live audio webcasts will be available in the Investors section of Kura’s website, with archived replays posted after each event.
Kura Oncology (Nasdaq: KURA) announced that on February 2, 2026 the Compensation Committee granted inducement nonstatutory stock options to four new employees totaling 69,750 shares under the 2023 Inducement Option Plan, as amended.
Each option has an exercise price of $8.27 (closing price on February 2, 2026) and vests over four years (25% at one year, then monthly over 36 months), subject to continued service and plan terms.
Kura Oncology (Nasdaq: KURA) reported the U.S. FDA approval and commercial launch of KOMZIFTI (ziftomenib) for adults with relapsed/refractory NPM1-mutated AML and disclosed preliminary commercial and collaboration financials. KOMZIFTI generated $2.1 million net product revenue from first sale (Nov 21–Dec 31, 2025). The company received $195 million in milestone payments, holds $667.3 million in cash and short-term investments as of Dec 31, 2025, and expects $45–$55 million non-cash collaboration revenue in 2026.
Key 2026 priorities include accelerating KOMZIFTI uptake, presenting KOMET-007/KOMET-017 data, expanding combinations, and advancing darlifarnib and next-generation programs.
Kura Oncology (Nasdaq: KURA) announced that on January 2, 2026 its Compensation Committee granted inducement nonstatutory stock options to three new employees under the company’s 2023 Inducement Option Plan.
The grants total 49,750 options with an exercise price of $10.34 per share (the closing price on January 2, 2026). The options vest over four years: 25% of the shares vest on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly over the following 36 months, subject to continued service. Grants are subject to the plan and applicable option agreements and were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (Nasdaq: KURA) and Kyowa Kirin reported KOMZIFTI (ziftomenib) combined with venetoclax and azacitidine showed strong activity and a manageable safety profile in NPM1-mutated and KMT2A-rearranged AML at ASH 2025.
Key data: newly diagnosed NPM1-m CRc 86% (37 evaluable) and CR 73% with 68% of CRc responders achieving molecular MRD negativity; median CR and OS not reached at 26.1-week median follow-up. In R/R NPM1-m ORR 65% (83 pts; CRc 48%; CRc median duration 39.9 weeks) and higher responses in venetoclax-naïve patients. In R/R KMT2A-r ORR 41% (CRc 28%; median OS 21.1 weeks). Combination was generally well tolerated.
Kura Oncology (Nasdaq: KURA) will host a virtual investor and analyst event on December 8, 2025 at 12:30 PM ET / 9:30 AM PT to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The presentation covers results scheduled for the 67th ASH Annual Meeting. Management and lead investigators will participate. A live webcast and replay will be available on the company website under Investors > Events and Presentations.
Kura Oncology (Nasdaq: KURA) announced the first U.S. commercial sale of KOMZIFTI™ (ziftomenib). Under Kura's collaboration and license agreement with Kyowa Kirin, the sale triggers a $135 million milestone payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025. This payment represents a near-term cash inflow tied to commercialization activity for the newly approved therapy.